Highlights:

亮点：

MELBOURNE, Australia, April 02, 2025 / Biotech Newswire / --

澳大利亚墨尔本，2025年4月2日 /生物技术新闻社/ --

Neurizon Therapeutics Limited

纽瑞森治疗有限公司

(ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent study undertaken in collaboration with

（ASX：NUZ 和 NUZOA）（“Neurizon”或“公司”），一家致力于推进神经退行性疾病治疗的临床阶段生物技术公司，很高兴地宣布与合作伙伴共同进行的一项独立研究的结果。

Tessara Therapeutics

特萨拉治疗学

(“Tessara”) will be presented by the group’s Principal Scientist and Alzheimer’s Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd. AD/PD is the preeminent international conference on Alzheimer’s and Parkinson’s diseases and related neurological disorders in Vienna, Austria, from 1 to 5 April..

“Tessara”将由该集团的首席科学家兼阿尔茨海默病专家马克·格林诺博士于4月2日至3日在AD/PD 2025科学与治疗进展会议上展示。AD/PD是关于阿尔茨海默病和帕金森病及相关神经系统疾病的国际顶级会议，将于4月1日至5日在奥地利维也纳举行。

The results are part of a study in ongoing collaboration with Tessara, a leading biotechnology company pioneering a new approach in 3D cell-based models of the brain, having developed its RealBrain® 3D human micro-tissues technology that replicates the biological complexity of the human brain in a scalable and reproducible manner.

这些结果是一项与Tessara公司持续合作研究的一部分，Tessara是一家领先的生物技术公司，致力于开创一种基于3D细胞的大脑模型的新方法，该公司开发了其RealBrain® 3D人类微组织技术，该技术能够以可扩展和可重复的方式复制人脑的生物复杂性。

Tessara has validated and recently launched two brain models: the ArtiBrain™ model (healthy human brain) and the ADBrain™ model (Alzheimer’s disease). Tessara has leveraged these models to explore the effect of Neurizon’s lead candidate, NUZ-001..

Tessara 已验证并近期推出了两个大脑模型：ArtiBrain™ 模型（健康人脑）和 ADBrain™ 模型（阿尔茨海默病）。Tessara 利用这些模型探索了 Neurizon 的主要候选药物 NUZ-001 的效果。

During the study, NUZ-001 and NUZ-001 Sulfone (major active metabolite) were tested in the ArtiBrain™ model over a three-day period at doses ranging from 5 μM to 50 μM. NUZ-001 demonstrated an excellent safety profile in Tessara’s RealBrain® micro-tissues. The compounds offered protection against a newly identified form of cell death, ferroptosis (induced by RSL3 exposure).

在研究期间，NUZ-001 和 NUZ-001 砜（主要活性代谢物）在 ArtiBrain™ 模型中进行了为期三天的测试，剂量范围为 5 μM 至 50 μM。NUZ-001 在 Tessara 的 RealBrain® 微组织中表现出优异的安全性。这些化合物对一种新发现的细胞死亡形式——铁死亡（由 RSL3 暴露诱导）提供了保护作用。

This unique type of programmed cell death is mechanistically different from apoptosis, autophagy, or necrosis and has been implicated in diseases where lipid peroxidation is a mechanism of neurodegeneration, such as Alzheimer's disease, Parkinson’s disease, and amyotrophic lateral sclerosis..

这种独特的程序性细胞死亡类型在机制上不同于细胞凋亡、自噬或坏死，并且已被证实在脂质过氧化是神经退行性机制的疾病中起作用，例如阿尔茨海默病、帕金森病和肌萎缩侧索硬化症。

Confocal imaging and subsequent neuronal network analysis, using Tessara’s algorithms, further revealed that NUZ-001 and NUZ-001 Sulfone increased neuronal (B3-tubulin+) branching. This suggests an effect on neural connectivity and plasticity, with longer-term drug treatments potentially being required to elicit an overall effect on network and synaptic density..

共聚焦成像和随后使用Tessara算法进行的神经元网络分析进一步揭示，NUZ-001和NUZ-001砜增加了神经元（B3-微管蛋白+）分支。这表明其对神经连接性和可塑性产生影响，可能需要较长时间的药物治疗才能对网络和突触密度产生整体效果。

Tessara’s Managing Director and Chief Executive Officer, Dr Christos Papadimitriou commented

特萨拉的董事总经理兼首席执行官克里斯托斯·帕帕季米特里奥博士评论道

: “We are delighted for Neurizon on the results they have generated in our ArtiBrain™ model. These findings indicate that short-term treatment with NUZ-001 and NUZ-001 Sulfone maintains an excellent safety profile in Tessara’s RealBrain® micro-tissues. In addition, the compounds appear to offer neuroprotective effects against ferroptosis and encourage neural branching, potentially boosting plasticity by enabling neurons to form additional connections.

“我们为Neurizon在我们的ArtiBrain™模型中取得的成果感到高兴。这些研究结果表明，短期使用NUZ-001和NUZ-001砜在Tessara的RealBrain®微组织中保持了出色的安全性。此外，这些化合物似乎对铁死亡具有神经保护作用，并促进神经分支，可能通过使神经元形成额外连接来增强可塑性。”

While further research is needed to clarify the mechanisms responsible for these benefits, current data suggest that longer-term treatment may enhance network density and overall plasticity. In humans, this could translate into tangible benefits in cognition, learning, memory, or resilience to neurodegenerative processes involved in diseases such as Alzheimer's disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS).'.

虽然还需要进一步的研究来阐明这些益处背后的作用机制，但目前的数据表明，较长时间的治疗可能会增强网络密度和整体可塑性。在人类中，这可能会转化为在认知、学习、记忆或对阿尔茨海默病、帕金森病和肌萎缩侧索硬化症（ALS）等疾病中涉及的神经退行性过程的抵抗力方面带来切实的好处。

As part of ongoing initiatives with Tessara, the therapeutic efficacy of NUZ-001 is now being assessed through other screening modalities, including Tessara’s ADBrain™ platform, for sporadic Alzheimer’s disease. Results from further testing are anticipated this quarter and will be used to assess the potential for NUZ to expand its lead asset into a broader range of indications..

作为与Tessara持续合作的一部分，NUZ-001的治疗效果正通过其他筛选方式（包括Tessara的ADBrain™平台）进行评估，针对散发性阿尔茨海默病。进一步测试的结果预计将在本季度公布，并将用于评估NUZ将其核心资产扩展到更广泛适应症的潜力。

Managing Director and Chief Executive Officer, Dr Michael Thurn commented

董事总经理兼首席执行官迈克尔·图恩博士评论道

: “These results provide initial validation of the broader potential use of NUZ-001 in other neurodegenerative diseases, highlighting its safety and efficacy in ArtiBrain™ 3D human micro-tissues model. The presentation of the study results at the world’s leading Alzheimer’s and Parkinson’s diseases and related neurological disorder conference in Vienna, is also a major milestone for the Company, which will provide strong independent support for our lead asset..

“这些结果初步验证了NUZ-001在其他神经退行性疾病中更广泛使用的潜力，突显了其在ArtiBrain™ 3D人体微组织模型中的安全性和有效性。该研究结果在维也纳举行的世界领先的阿尔茨海默病和帕金森病及相关神经系统疾病会议上的展示，也是公司的一个重要里程碑，将为我们的核心资产提供强有力的独立支持。”

“I would like to take this opportunity to thank Tessara Therapeutics for the excellent collaboration to date, which will continue as we assess NUZ-001’s potential as a treatment of Alzheimer’s disease in the ADBrain™ model. These additional results are expected to materialise this quarter and have the potential to highlight NUZ-001’s potential in another widespread and debilitating condition.”.

“我要借此机会感谢Tessara Therapeutics迄今为止的卓越合作，我们评估NUZ-001作为阿尔茨海默病治疗药物在ADBrain™模型中的潜力时，这种合作还将继续。这些更多的结果预计将在本季度实现，并有可能突显NUZ-001在另一种广泛且使人衰弱的疾病中的潜力。”

A copy of the poster presentation by Dr Greenough at AD/PD can be found in the original announcement on Neurizon Therapeutics Investor Hub.

可以在Neurizon Therapeutics投资者中心的原始公告中找到格林诺博士在AD/PD上的海报展示副本。

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

本公告已获Neurizon Therapeutics Limited董事会授权发布。

For high resolution please click the image.

请单击图像以获得高分辨率。

About

关于

Tessara Therapeutics

特萨拉治疗学

Tessara Therapeutics is a Melbourne-based biotechnology company pioneering novel drug discovery technologies for neurological and neurodegenerative diseases. Through its proprietary RealBrain® platform, Tessara has developed the first scalable, reproducible 3D human brain micro-tissue models that closely replicate both healthy and diseased neural physiology.

Tessara Therapeutics是一家位于墨尔本的生物技术公司，致力于开发针对神经和神经退行性疾病的新型药物发现技术。通过其专有的RealBrain®平台，Tessara开发了首个可扩展、可重复的3D人脑微组织模型，这些模型能够高度复制健康和患病的神经生理状态。

These models include ArtiBrain, representing the healthy brain, and ADBrain, capturing sporadic Alzheimer’s disease cases. By enabling cost-effective, high-throughput screening and delivering predictive, human-relevant data, Tessara’s approach accelerates discovery timelines, enhances the likelihood of successful clinical trials, and supports the industry-wide shift to non-animal research..

这些模型包括代表健康大脑的ArtiBrain，以及捕捉偶发性阿尔茨海默病病例的ADBrain。通过实现经济高效的高通量筛选并提供与人类相关的预测数据，Tessara的方法加速了发现时间线，提高了临床试验成功的机会，并支持了全行业向非动物研究的转变。

About

关于

Neurizon Therapeutics Limited

纽瑞佐恩治疗有限公司

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.  Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001’s potential for broader neurodegenerative applications.

Neurizon Therapeutics Limited（ASX：NUZ）是一家临床阶段的生物技术公司，致力于推进神经退行性疾病的治疗方法。Neurizon正在开发其主要候选药物NUZ-001，用于治疗肌萎缩侧索硬化症（ALS），这是运动神经元病最常见的形式。Neurizon的战略是加快患者获得有效的ALS治疗，同时探索NUZ-001在更广泛的神经退行性疾病中的潜力。

Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders..

通过国际合作和严格的临床项目，Neurizon致力于为受复杂神经疾病影响的患者和家庭创造新的希望。

Neurizon Investor Hub

Neurizon投资者中心

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.

我们鼓励您利用我们的投资者中心，就本公告或与Neurizon相关的其他方面提出任何询问。

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

该平台提供了一个提交问题、分享评论以及查看关键公告视频摘要的机会。

To access Neurizon Investor Hub visit

访问 Neurizon 投资者中心请前往

https://investorhub.neurizon.com

https://investorhub.neurizon.com

Contacts

联系人

Neurizon Therapeutics Limited

纽瑞森治疗有限公司

Dr. Michael Thurn

迈克尔·图恩博士

Managing Director and Chief Executive Officer

总经理兼首席执行官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+61 (3) 9692 7222

+61 (3) 9692 7222

Lidija Damjanovic

利迪娅·达米亚诺维奇

Head of Marketing and Corporate Affairs

市场与企业事务主管

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+61 (0)425 700 504

+61 (0)425 700 504

Keywords: Neuroprotective Agents; Tubulin; Neurodegenerative Diseases; Alzheimer Disease; Ferroptosis; Parkinson Disease; Neurons; Brain; Neuronal Plasticity; Australia; NUZ-001; NUZ-001 Sulfone; Human 3D brain model; Tessara Therapeutics; RealBrain® 3D human micro-tissues; ArtiBrain model; ADBrain model; Neuroprotective properties; Neuroplasticity; Neuronal branching; Ferroptosis; RSL3 exposure; Amyotrophic lateral sclerosis (ALS); Confocal imaging; Neuronal network analysis; Neural connectivity; Synaptic density; Cognitive benefits; Learning and memory; Neurodegeneration; AD/PD 2025 Advances in Sciences & Therapy Conference; Vienna, Austria; Neurizon Therapeutics; Dr Mark Greenough; Dr Christos Papadimitriou; Dr Michael Thurn.

关键词：神经保护剂；微管蛋白；神经退行性疾病；阿尔茨海默病；铁死亡；帕金森病；神经元；大脑；神经可塑性；澳大利亚；NUZ-001；NUZ-001砜；人类3D脑模型；Tessara Therapeutics；RealBrain® 3D人类微组织；ArtiBrain模型；ADBrain模型；神经保护特性；神经可塑性；神经元分支；铁死亡；RSL3暴露；肌萎缩侧索硬化症（ALS）；共聚焦成像；神经网络分析；神经连接性；突触密度；认知益处；学习与记忆；神经退化；2025年AD/PD科学与治疗进展会议；奥地利维也纳；Neurizon Therapeutics；马克·格林诺博士；克里斯托斯·帕帕迪米特里奥博士；迈克尔·图恩博士。

Source: Biotech Newswire

来源：生物技术新闻社